Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
31 March 2017
E-002437-17
Question for written answer
to the Commission
Rule 130
Maria Spyraki (PPE)

 Subject:  Procedure for financing innovative medicines
 Answer(s) 

The Ministry of Health has proposed new measures as regards the approval of compensation for innovative medicines which would introduce new inclusion criteria for formulations included in the positive list that are compensated by the National Organisation for Healthcare Provision (EOPYY). Under the measures, compensation for a new pharmaceutical formulation would require the formulation to have been assessed and compensated at the same time in six European countries (England, Italy, Spain, Sweden, Portugal and France) through the Medical Technology Assessment (MTA) system.

Since a new medicine needs about two years to be compensated in Greece and, under the new measures, the introduction of innovation is expected to be delayed considerably further:

How will the MTA criterion be introduced in a way that avoids delays?

A medicine is rated as positive when its use is fully recommended or is recommended with limitations — whether financial or clinical — and, moreover, a particular technology may receive completely opposing recommendations from different MTA agencies, resulting in it being fully accepted in one environment, accepted with restrictions in another and rejected in a third. Given the above, how will the criterion of ‘positive decision’ apply?

Since a number of rare or serious diseases rely on innovative treatments, how will the quick and timely circulation of innovative medicines in the Greek market be ensured by applying the above criterion and without delays caused by procedural issues?

Original language of question: EL 
Last updated: 26 April 2017Legal notice